Asepticys Overview

  • Founded
  • 2015
  • Status
  • Private
  • Employees
  • 3
  • Latest Deal Type
  • Series A1
  • Latest Deal Amount
  • $3M
Latest Deal Amount
  • Investors
  • 4

Asepticys General Information


Developer of infection protection drugs designed to shield from hidden microbial threats. The company's drugs combat skin and wound infections caused by protozoa, bacteria, fungi, and viruses and are safe for use on human skin, eyes and tissue, enabling patients to use the medicine on their skin, eyes, and tissue and protect their health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 204 South Union Street
  • Alexandria, VA 22314
  • United States
+1 (703) 000-0000

Asepticys Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Asepticys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 28-Nov-2018 $3M 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A1) 16-Apr-2018 00.000 00.000 Completed Clinical Trials - General
2. Early Stage VC 29-Nov-2016 $2M $3.58M Completed Startup
1. Early Stage VC (Series A) 08-Mar-2016 $1.57M $1.57M 0000 Completed Startup
To view Asepticys’s complete valuation and funding history, request access »

Asepticys Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view Asepticys’s complete cap table history, request access »

Asepticys Executive Team (4)

Name Title Board Seat Contact Info
Todd Rands JD Chief Executive Officer, President & Board Member
David Feigal MD Chief Technology Officer
Rebecca Metzinger MD Co-Founder, Medical Director, Ophthalmology Products & Advisor
Chad Roy Ph.D Co-Founder, Research & Development Director & Board Member
To view Asepticys’s complete executive team members history, request access »

Asepticys Board Members (5)

Name Representing Role Since
Bruce Cohen Ph.D Self Co-Chairman 000 0000
Chad Roy Ph.D Asepticys Co-Founder, Research & Development Director & Board Member 000 0000
Fred Eshelman Eshelman Ventures Co-Chairman 000 0000
Todd Rands JD Asepticys Chief Executive Officer, President & Board Member 000 0000
Tom Crawford Self Board Member 000 0000
To view Asepticys’s complete board members history, request access »

Asepticys Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asepticys Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
12 Point Ventures Venture Capital Minority 000 0000 000000 0
Tom Crawford Angel (individual) Minority 000 0000 000000 0
Eshelman Ventures Venture Capital Minority 000 0000 000000 0
John T. Siegel Revocable Trust Other Minority 000 0000 000000 0
To view Asepticys’s complete investors history, request access »